NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Cardiovascular > AI detects life-threatening blood vessel inflammation from COVID-19 variants

AI detects life-threatening blood vessel inflammation from COVID-19 variants

8 June 2021 · Listed under Cardiovascular, COVID-19, NIHR-BHF

New artificial intelligence (AI) technology to scan for heightened blood vessel inflammation can calculate a person’s risk of death from COVID-19 and COVID-19 variants.

Image: National Institute of Allergy and Infectious Diseases NIH

The technology could be used to tailor their treatment and give them the best chance of recovery, according to new research funded by the British Heart Foundation (BHF) and presented today at the British Cardiovascular Society conference.

Severe cases of COVID-19 have been associated with a ‘cytokine storm’, where the virus ‘spike’ protein causes the immune system to go into overdrive and produces a surge of damaging molecules called cytokines.

Now, by using routine chest CT scans, researchers at the University of Oxford have developed a COVID-19 ‘signature’ using machine learning. The ‘signature’ detects biological red flags in the fat surrounding the blood vessels in the chest to measure the level of cytokine-driven vascular inflammation in people infected with the virus.

The team applied the COVID-19 signature to CT chest scans of 435 people admitted to hospitals in Oxford, Leicester and Bath, and compared the degree of inflammation and risk of death in people with and without COVID-19.

For patients admitted to hospital, the level of cytokine-driven inflammation in the blood vessels was much higher in those with COVID-19, and even greater in patients infected by the B.1.1.7 or ‘alpha’ variant first identified in the UK.

Those with a high level of vascular inflammation were up to eight times more likely to die in hospital, and were most likely to respond well to the anti-inflammatory drug Dexamethasone. COVID-19 patients with high vascular inflammation treated with Dexamethasone had a six-fold reduction in risk of dying compared to COVID-19 patients who were not given the drug.

By using this tool to obtain an inflammation score, COVID-19 patients found to have a lot of inflammation in their blood vessels, and therefore increased risk of death, could potentially be given anti-inflammatory drugs to reduce their risk and help their long-term recovery. Clinical trials are now looking into the effectiveness of this approach.

Now, the researchers will continue to look at the impact of coronavirus variants as they emerge. They say that their technology may have immense power to easily track the long-term cardiovascular effects of COVID-19 and quickly respond to future viruses.

Professor Charalambos Antoniades (pictured left), Professor of Cardiovascular Medicine and BHF Senior Clinical Research Fellow at the University of Oxford’s Radcliffe Department of Medicine, said: “We have built an incredibly adaptable AI platform that tracks vascular disease by decoding information from blood vessel images obtained routinely during hospital admission, and integrating it with a large RNA bioresource from human tissue biopsies.

“By simply adding in one extra step to the routine care of people admitted to hospital with COVID-19 who already have a CT scan, we can now detect patients at high risk of life-threatening complications and could potentially tailor their treatment to aid long-term recovery.”

Prof Antoniades, who is supported by the NIHR Oxford Biomedical Research Centre (BRC), added: “The benefits don’t stop there. We know that this exaggerated immune response to the virus can also cause abnormal blood clotting, and so we are developing this AI platform to specifically identify COVID-19 patients who are most at risk of having a future heart attack or stroke. We can also pivot our platform with ease to develop a new scanning ‘signature’ to better understand future viruses and diseases that take hold of our population.”

Professor James Leiper, Associate Medical Director at the British Heart Foundation, said: “Over the past year we have supported our scientists to direct their expertise to help the global effort in understanding COVID-19. This research clearly demonstrates that COVID-19 is a powerful virus that can wreak havoc on our circulatory system, and that different variants are associated with different levels of risk. There are still a lot of unknowns relating to how the virus can impact our health in the long term, but this AI tool could ultimately help to save lives.”

This research is one of the six research programmes chosen as UK Flagship Projects, all of which aim to improve care for people with heart and circulatory disease suffering from COVID-19. The initiative builds on an existing partnership between the BHF and the National Institute for Health Research (NIHR), hosted by the Oxford BRC, and provides a new framework for the rapid set-up and delivery of urgent, high impact COVID-19 research projects across the UK.

← Study confirms longer-term lung damage after COVID-19
RECOVERY trial finds aspirin does not improve survival for hospitalised COVID-19 patients →

News

  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
  • Oxford’s medical, health and life sciences research excellence recognised 12 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre